Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
XWELLSTU:V9G0 27 Gross Margin % is 41.26% as of Jun. 2026, which is 90% above its 10-year median of 21.76. GuruFocus rates STU:V9G0 with a GF Score™ of 27/100 and a GF Value™ of €2.45. The stock has 4 warning signs investors should review. Among 194 Medical Diagnostics & Research companies, XWELL ranks worse than 70.62% on this metric.
Gross Margin % is calculated as gross profit divided by its revenue. XWELL's Gross Profit for the
three
months ended in Jun. 2026 was €2.56 Mil. XWELL's Revenue for the
three
months ended in Jun. 2026 was €6.20 Mil. Therefore, XWELL's Gross Margin % for the quarter that ended in Jun. 2026 was 41.26%.
The historical rank and industry rank for XWELL's Gross Margin % or its related term are showing as below:
STU:V9G0'
s Gross Margin % Range Over the Past 10 Years
Min: -42.91 Med: 21.76 Max: 43.87
Current: 34.35
During the past 13 years, the highestGross Margin % of XWELL was 43.87%. The lowest was -42.91%. And the median was 21.76%.
STU:V9G0's Gross Margin % is ranked worse than 70.62% of 194
companies
in the Medical Diagnostics & Research industry
Industry Median: 50.825
vs STU:V9G0: 34.35
XWELL had a gross margin of 41.26% for the quarter that ended in Jun. 2026 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for XWELL was 0.00% per year.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
XWELL had a gross margin of 41.26% for the quarter that ended in Jun. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
XWELL Gross Margin % Related Terms
XWELL Gross Margin % Historical Data
* Premium members only.
The historical data trend for XWELL's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:V9G0 vs MBAI, NDRA, BIAF: Gross Margin % Comparison
For the Diagnostics & Research subindustry, XWELL's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
XWELL Gross Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, XWELL's Gross Margin % distribution charts can be found below:
* The bar in red indicates where XWELL's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
XWELL (STU:V9G0) has a Gross Margin % of 41.26% as of Jun. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on XWELL and its competitors. This is 90% above median its historical median of 21.76. According to the industry distribution chart, XWELL ranks #137 out of 194 companies in the Medical Diagnostics & Research industry, placing it in the top 70.6%.
Is XWELL's Gross Margin % too high?
XWELL's current Gross Margin % of 41.26% is 90% above median its 10-year median of 21.76. The Medical Diagnostics & Research industry median Gross Margin % is 50.83. XWELL's value of 41.26% is 18.8% below this industry median. Based on the distribution chart, XWELL ranks #137 out of 194 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, XWELL has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does XWELL's Gross Margin % compare to MBAI and NDRA?
According to the Medical Diagnostics & Research industry distribution chart, XWELL ranks #137 out of 194 companies for Gross Margin %. This places XWELL in the lower half of its industry. The industry median Gross Margin % is 50.83. XWELL's value of 41.26% is 18.8% below this benchmark. While the company's 10-year median is 21.76 vs. the industry median of 50.83, XWELL has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Medical Diagnostics & Research company?
The median Gross Margin % among Medical Diagnostics & Research companies is 50.83, based on 194 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. XWELL's current Gross Margin % of 41.26% is 18.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on XWELL and its competitors. For the Medical Diagnostics & Research industry, the median Gross Margin % is 50.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. XWELL's current Gross Margin % is 41.26%, which is 90% above median its own 10-year median of 21.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is XWELL stock overvalued right now?
XWELL (STU:V9G0) has a current Gross Margin % of 41.26%. The stock's GF Value™ is €2.45, compared to a current price of €2.96 — trading 20.8% above its estimated fair value. The current Gross Margin % is 41.26%, which is 90% above median its 10-year median of 21.76 and 18.8% below the Medical Diagnostics & Research industry median of 50.83. XWELL's overall GF Score™ is 27/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For XWELL (STU:V9G0), the current Gross Margin % is 41.26% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is XWELL (STU:V9G0) Overvalued in 2026?
Based on GuruFocus' analysis, XWELL stock appears to be overvalued.
The current stock price of €2.96 is trading 20.8% above its estimated GF Value™ of €2.45.
Key valuation signals for STU:V9G0:
Gross Margin %: 41.26% (90% above median its 10-year median of 21.76)
GF Value™: €2.45 vs. price of €2.96 (20.8% above fair value)
Industry Position: 18.8% below the Medical Diagnostics & Research median (#137 of 194)
No single metric tells the full story. See the STU:V9G0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
XWELL Inc is an international wellness organization dedicated to delivering restorative and health-focused services to travelers through its three reportable operating segments: XpresSpa, XpresTest, and Naples Wax Center. The XpresSpa segment, which generates maximum revenue, operates spa service locations in airports, offering massage, skincare, and travel products. The XpresTest segment provides aircraft wastewater and passenger nasal sampling through the CDC's bio-surveillance program. The Naples Wax Center segment operates six locations offering face and body waxing, skincare services, and cosmetic products. The Company generates maximum revenue from the United States.
27GF Score
Get the complete analysis for STU:V9G0
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:V9G0 has been successfully added to your 
